Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–2037.

In supplemental Table 3, in the second of the 3 column subheadings under “Relapsed/Refractory” and “Total,” “160 mg qd” should read “160 mg bid.” In supplemental Table 5, row 7, “TEAE” should read “treatment-related TEAE.” The corrected supplemental data file has been placed in the online version of the article.